Portable muon beam could accelerate archaeology scans
Nature, Published online: 10 October 2025; doi:10.1038/d41586-025-03245-8 Laser plasma device could be light enough to be used on the field.
STAT+: Key GOP lawmaker tones down rhetoric on medical care for immigrants
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Three
AstraZeneca kicks off construction of $4.5B API plant in Virginia
AstraZeneca has broken ground on a $4.5 billion manufacturing facility near Charlottesville, Virginia, confirming a report about its location six weeks ago when state lawmakers approved an economic development package for the
First gene-edited pig liver transplanted into a living person
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. A STAT editor spotted somebody yesterday wearing a t-shirt that read: “I Tylenol.” That
Lupin rides the onshoring wave, pledging $250M to build new respiratory production plant in Fla.
Lupin expects to invest a combined $250 million—covering R&D, infrastructure and capital expenditures over five years—to build a new pharmaceutical production plant in Coral Springs, Florida. The site will focus on the
Strong Social Relationships Promote Longevity by Slowing Cellular Aging
A new study found having a variety of strong social ties throughout life was tied to slowed biological aging and less chronic inflammation.
OXB kicks off US expansion, buying viral vector plant in N.C. from National Resilience for $4.5M
Less than two months after OXB revealed a plan to expand its operations in the U.S., the U.K.-based cell and gene therapy manufacturer has purchased a viral vector plant in North Carolina
Eli Lilly earmarks $1B-plus for contract manufacturing partnerships in India
The company will work with new local contract manufacturers in India to boost supply of its key medicines.
FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing
The FDA unveiled a new pilot program that aims to speed up review times for generic drugmakers who test and manufacture their products in the U.S. Separately, the agency met with industry
Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate
The initial part of the up-to-$339 million funding will largely be used to establish U.S. manufacturing for the non-vaccine flu preventive candidate, with additional options tied to further clinical studies, Cidara said.